JP2021512099A5 - - Google Patents

Info

Publication number
JP2021512099A5
JP2021512099A5 JP2020541689A JP2020541689A JP2021512099A5 JP 2021512099 A5 JP2021512099 A5 JP 2021512099A5 JP 2020541689 A JP2020541689 A JP 2020541689A JP 2020541689 A JP2020541689 A JP 2020541689A JP 2021512099 A5 JP2021512099 A5 JP 2021512099A5
Authority
JP
Japan
Prior art keywords
group
ttds
palm
amino acid
stea
Prior art date
Application number
JP2020541689A
Other languages
English (en)
Japanese (ja)
Other versions
JP7295871B2 (ja
JPWO2019149782A5 (https=
JP2021512099A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/052298 external-priority patent/WO2019149782A1/en
Publication of JP2021512099A publication Critical patent/JP2021512099A/ja
Publication of JP2021512099A5 publication Critical patent/JP2021512099A5/ja
Publication of JPWO2019149782A5 publication Critical patent/JPWO2019149782A5/ja
Application granted granted Critical
Publication of JP7295871B2 publication Critical patent/JP7295871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541689A 2018-01-31 2019-01-30 修飾された脂質化リラキシンb鎖ペプチドおよびその治療的使用 Active JP7295871B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
EP18305094.7 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (4)

Publication Number Publication Date
JP2021512099A JP2021512099A (ja) 2021-05-13
JP2021512099A5 true JP2021512099A5 (https=) 2022-02-02
JPWO2019149782A5 JPWO2019149782A5 (https=) 2022-02-02
JP7295871B2 JP7295871B2 (ja) 2023-06-21

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541689A Active JP7295871B2 (ja) 2018-01-31 2019-01-30 修飾された脂質化リラキシンb鎖ペプチドおよびその治療的使用

Country Status (29)

Country Link
US (3) US10961295B2 (https=)
EP (1) EP3746467B1 (https=)
JP (1) JP7295871B2 (https=)
KR (1) KR102755938B1 (https=)
CN (1) CN111770934B (https=)
AR (1) AR114325A1 (https=)
AU (1) AU2019214358B2 (https=)
BR (1) BR112020014834A2 (https=)
CA (1) CA3089657A1 (https=)
CO (1) CO2020008308A2 (https=)
DK (1) DK3746467T3 (https=)
ES (1) ES3058633T3 (https=)
FI (1) FI3746467T3 (https=)
HR (1) HRP20260016T1 (https=)
IL (2) IL316406A (https=)
LT (1) LT3746467T (https=)
MA (1) MA52994A (https=)
MX (1) MX2020008096A (https=)
MY (1) MY199821A (https=)
NZ (1) NZ766762A (https=)
PH (1) PH12020551118A1 (https=)
PL (1) PL3746467T3 (https=)
PT (1) PT3746467T (https=)
RS (1) RS67606B1 (https=)
SG (1) SG11202006903WA (https=)
SI (1) SI3746467T1 (https=)
TW (1) TWI763972B (https=)
UY (1) UY38069A (https=)
WO (1) WO2019149782A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MA52994A (fr) 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
US20240400638A1 (en) * 2021-08-23 2024-12-05 Guido MAGNI Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
KR20260035823A (ko) 2023-05-18 2026-03-13 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923283A2 (pt) * 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
EP2726502A1 (en) * 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−2を調製する方法
US20160152679A1 (en) 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
CN105792851B (zh) * 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
EP3838285A1 (en) * 2014-04-22 2021-06-23 TXP Pharma GmbH Peptide analogues with branched amino acid probe(s)
CN110637027B (zh) * 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
MA52994A (fr) 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
US20240400638A1 (en) * 2021-08-23 2024-12-05 Guido MAGNI Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Similar Documents

Publication Publication Date Title
JP2021512099A5 (https=)
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
JP2020073472A5 (https=)
JP2014509838A5 (https=)
JP2013500990A5 (https=)
JPWO2019149782A5 (https=)
EP2858661B1 (en) Stabilized antiviral fusion helices
JP2020502051A5 (https=)
JP6633523B2 (ja) Psd−95の二量体阻害剤脂肪酸誘導体
JP2010535714A5 (https=)
JP2015533833A5 (https=)
JP2010502734A5 (https=)
JP2012211164A5 (https=)
JP2012531219A5 (https=)
JP2011525190A5 (https=)
JP2009108078A5 (https=)
JP2015534972A5 (https=)
CN1662551A (zh) 前列腺素e2受体亚型ep4的拮抗肽
JP2025172864A5 (https=)
JP2024532403A (ja) 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ
JP2018536645A5 (https=)
CN1041524C (zh) 由c-活性蛋白质片段衍生的寡肽及其药物组合物
JP2018526987A5 (https=)
JP2018507187A5 (https=)
IL299778A (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease